Fundz

Humacyte, Inc. reported raising $150 Million in an initial SEC Form D filing, from an offering of $150 Million

PUBLIC · HUMAJun 26, 2018

Amount Raised

$150 Million

$150 Million sold, per SEC Form D (first sale Jun 26, 2018)

Round Type

Venture

DurhamBiotechnologyHealth CareMedical Device

Who else raised in Medical Device and Biotechnology around the same time

Companies in the same sectors as Humacyte that raised within 45 days of this round, from Fundz verified event records.

Who to call at Humacyte, and when

A new round usually means Humacyte is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Humacyte raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Humacyte, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Humacyte. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Humacyte

Location

Durham, North Carolina, United States

About

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Humacyte raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts22 people are listed at Humacyte. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Humacyte's next move

See what Strategic adds

Humacyte raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.